Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
Bmc Medicine
Yang, Guangjian G; Xu, Haiyan H; Yang, Yaning Y; Zhang, Shuyang S; Xu, Fei F; Hao, Xuezhi X; Li, Junling J; Xing, Puyuan P; Hu, Xingsheng X; Liu, Yutao Y; Wang, Lin L; Lin, Lin L; Wang, Zhijie Z; Duan, Jianchun J; Wang, Jie J; Wang, Yan Y
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Cancer Research
Kalra, Rashi R; Chen, Ching Hui CH; Wang, Junkai J; Salam, Ahmad Bin AB; Dobrolecki, Lacey E LE; Lewis, Alaina A; Sallas, Christina C; Yates, Clayton C CC; Gutierrez, Carolina C; Karanam, Balasubramanyam B; Anurag, Meenakshi M; Lim, Bora B; Ellis, Matthew J MJ; Kavuri, Shyam M SM
Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
International Journal Of Molecular Medicine
Chevrier, Sandy S; Brasselet, Astrid A; Carnet, Marion M; Chevriaux, Angélique A; Gibeaud, Anne A; Jourdain, Marine M; Mananet, Hugo H; Truntzer, Caroline C; Beltjens, Françoise F; Charon-Barra, Céline C; Arnould, Laurent L; Albuisson, Juliette J; Comte, Anthony A; Derangère, Valentin V; Goussot, Vincent V; Boidot, Romain R
Publication Date: 2022-05
Variant appearance in text: ERBB2: 2180G>C; Gly727Ala
The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, RB1 and ERBB2 Somatic Mutations.
Journal Of Personalized Medicine
Kałużewski, Tadeusz T; Przybylski, Grzegorz K GK; Bednarek, Michał M; Glazar, Sławomir S; Grabiec, Magdalena M; Jędrzejczyk, Adam A; Kępczyński, Łukasz Ł; Kubiak, Izabela I; Kucharska, Dorota D; Morel, Agnieszka A; Owczarek, Magdalena M; Rożniecki, Marek M; Sałamunia, Jordan J; Szewczyk, Dominika D; Szwalski, Jarosław J; Kałużewski, Bogdan B
Publication Date: 2021-04-30
Variant appearance in text: ERBB2: 2180G>C; Gly727Ala
Genomic profile of advanced breast cancer in circulating tumour DNA.
Nature Communications
Kingston, Belinda B; Cutts, Rosalind J RJ; Bye, Hannah H; Beaney, Matthew M; Walsh-Crestani, Giselle G; Hrebien, Sarah S; Swift, Claire C; Kilburn, Lucy S LS; Kernaghan, Sarah S; Moretti, Laura L; Wilkinson, Katie K; Wardley, Andrew M AM; Macpherson, Iain R IR; Baird, Richard D RD; Roylance, Rebecca R; Reis-Filho, Jorge S JS; Hubank, Michael M; Faull, Iris I; Banks, Kimberly C KC; Lanman, Richard B RB; Garcia-Murillas, Isaac I; Bliss, Judith M JM; Ring, Alistair A; Turner, Nicholas C NC
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women.
Nature Communications
Romero-Cordoba, Sandra L SL; Salido-Guadarrama, Ivan I; Rebollar-Vega, Rosa R; Bautista-Piña, Veronica V; Dominguez-Reyes, Carlos C; Tenorio-Torres, Alberto A; Villegas-Carlos, Felipe F; Fernández-López, Juan C JC; Uribe-Figueroa, Laura L; Alfaro-Ruiz, Luis L; Hidalgo-Miranda, Alfredo A
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Molecular Oncology
Bertucci, François F; Rypens, Charlotte C; Finetti, Pascal P; Guille, Arnaud A; Adélaïde, José J; Monneur, Audrey A; Carbuccia, Nadine N; Garnier, Séverine S; Dirix, Piet P; Gonçalves, Anthony A; Vermeulen, Peter P; Debeb, Bisrat G BG; Wang, Xiaoping X; Dirix, Luc L; Ueno, Naoto T NT; Viens, Patrice P; Cristofanilli, Massimo M; Chaffanet, Max M; Birnbaum, Daniel D; Van Laere, Steven S
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Npj Precision Oncology
Medford, Arielle J AJ; Dubash, Taronish D TD; Juric, Dejan D; Spring, Laura L; Niemierko, Andrzej A; Vidula, Neelima N; Peppercorn, Jeffrey J; Isakoff, Steven S; Reeves, Brittany A BA; LiCausi, Joseph A JA; Wesley, Benjamin B; Malvarosa, Giuliana G; Yuen, Megan M; Wittner, Ben S BS; Lawrence, Michael S MS; Iafrate, A John AJ; Ellisen, Leif L; Moy, Beverly B; Toner, Mehmet M; Maheswaran, Shyamala S; Haber, Daniel A DA; Bardia, Aditya A
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
Journal Of The National Cancer Institute
Loree, Jonathan M JM; Bailey, Ann M AM; Johnson, Amber M AM; Yu, Yao Y; Wu, Wenhui W; Bristow, Christopher A CA; Davis, Jennifer S JS; Shaw, Kenna R KR; Broaddus, Russell R; Banks, Kimberly C KC; Lanman, Richard B RB; Meric-Bernstam, Funda F; Overman, Michael J MJ; Kopetz, Scott S; Raghav, Kanwal K
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Plos One
Janjigian, Yelena Y YY; Vakiani, Efsevia E; Ku, Geoffrey Y GY; Herrera, Jessica M JM; Tang, Laura H LH; Bouvier, Nancy N; Viale, Agnès A; Socci, Nicholas D ND; Capanu, Marinela M; Berger, Michael M; Ilson, David H DH